ロード中...
Recent advances in triple negative breast cancer: the immunotherapy era
BACKGROUND: Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheless, despi...
保存先:
| 出版年: | BMC Med |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6507064/ https://ncbi.nlm.nih.gov/pubmed/31068190 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-019-1326-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|